BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The BioCalendar
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260421T130000
DTEND;TZID=America/Los_Angeles:20260421T140000
DTSTAMP:20260608T065013
CREATED:20260318T144018Z
LAST-MODIFIED:20260318T144018Z
UID:10033-1776776400-1776780000@thebiocalendar.com
SUMMARY:Small Molecule Drug Product Capabilities Update
DESCRIPTION:Watch leading CDMOs share their current capabilities\, facility locations\, and timelines – to help you identify options for your development and manufacturing needs. \nWhat can you expect? – Short\, digital presentations to give you an inside look at the available capacity of industry suppliers. You will have the opportunity to ask questions of each CDMO to better understand if they can meet your needs – all from the convenience of your computer! \nPlease note that this event is for biopharma companies seeking to connect with CDMOs who have the capabilities that fit their needs.
URL:https://thebiocalendar.com/event/small-molecule-drug-product-capabilities-update/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/Biocal-11.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260421T110000
DTEND;TZID=America/Los_Angeles:20260421T120000
DTSTAMP:20260608T065013
CREATED:20260327T122913Z
LAST-MODIFIED:20260327T122913Z
UID:10096-1776769200-1776772800@thebiocalendar.com
SUMMARY:We Mapped What Sites Actually Do to Prepare Source Docs - The Results Are Eye-Opening
DESCRIPTION:In late 2025\, Tufts CSDD and CRIO conducted a survey among a global community of investigative sites to better understand how sites translate clinical trial protocols and related information into practical tools such as template source documents\, study plans\, calendars\, worksheets and shadow charts for the purposes of ensuring compliant\, efficient\, and high-quality data collection. In total\, 209 sites from a variety of settings responded. This session will review key takeaways from this research and discuss their implications.  \nThis source preparation process is not well understood and the lack of standardized terms describing the process are a source of confusion.  At the same time\, it is widely acknowledged that the process of source document preparation at investigative sites is inefficient and highly fragmented. This webinar will provide an overview to the comprehensive mapping of systems and workflows that investigative sites use to capture\, manage and transmit clinical research data; characterize pain points and challenges that drive delays; and identify opportunities to improve efficiency\, speed and quality. \nThe webinar will begin with a short presentation of the study results. Next\, a panel of investigative site representatives will discuss the findings and insights. \nKey learning objectives: \nReview the typical site workflow for preparing source documents and the critical and rate-limiting documents needed\n– Examine the roles and work effort required to prepare source documents and how this varies based on protocol complexity\n– Discuss the wide range of paper and electronic systems that sites use to capture relevant study information\n– Identify opportunities for sponsors\, sites and service providers to enhance the protocol-guided source preparation process and accelerate study activation times
URL:https://thebiocalendar.com/event/we-mapped-what-sites-actually-do-to-prepare-source-docs-the-results-are-eye-opening/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-21-26-CRIO-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260421T110000
DTEND;TZID=America/Los_Angeles:20260421T120000
DTSTAMP:20260608T065013
CREATED:20260325T132859Z
LAST-MODIFIED:20260325T132859Z
UID:10065-1776769200-1776772800@thebiocalendar.com
SUMMARY:Unlocking the next wave of cancer vaccines: Advancing mRNA-LNP delivery and small-scale manufacturing
DESCRIPTION:Personalized cancer vaccines (PCVs) are reshaping immuno-oncology. However\, translating these therapies into the clinic remains challenging. The progress is often slowed by critical bottlenecks – from suboptimal delivery\, limited access to novel lipid nanoparticle (LNP) formulations\, to a lack of manufacturing technologies designed for small-scale clinical production.  \nThis webinar explores how optimized ionizable LNP formulations improve the delivery of multi-epitope mRNA cancer vaccine candidates while supporting safety and immune-targeted expression. We will share findings from repeat intramuscular dosing studies demonstrating favorable tolerability and extended survival in tumor‑bearing mice.  \nYou will also learn how pairing advanced LNP design with small‑scale clinical manufacturing technologies enables a smoother transition from early development to clinical evaluation. By aligning formulation strategy with scalable process designs\, teams can ensure PCV candidates are potent and ready for clinical translation. \nJoin this webinar to learn:\n~   Why current PCV delivery strategies fall short—and how next-generation ionizable lipid formulations address safety and tissue-targeting limitations\n~   How optimized ionizable lipids enhance effective LNP-mediated delivery\, mRNA translation\, and antigen presentation for multi‑epitope mRNA cancer vaccines\n~   Key findings from repeated intramuscular dosing studies\, including maintained critical quality attributes (CQAs)\, no detectable toxicity\, and extended survival in tumor‑bearing mice\n~   Practical considerations for building PCV manufacturing workflows that transition seamlessly from concept to clinic using technologies purpose-built for small-scale clinical production \nSpeaker:\nMartin Rabel\nGlobal Sales Specialist\, BioPharma Services\, Cytiva\nMartin Rabel\, Ph.D.\, leads the commercial strategy for Cytiva’s BioPharma Services portfolio across EMEA and APAC. In this role\, he supports the advancement of nucleic acid–based therapies by enabling access to Cytiva’s proprietary lipid nanoparticle (LNP) platform and its integrated suite of nanoparticle development\, analytical\, and cGMP-compliant manufacturing services.\nMartin plays a key part in shaping and expanding this rapidly growing area of Cytiva’s offering. With a background as a trained Pharmacist and deep technical expertise in nanomedicine and RNA–LNP technologies\, he is committed to delivering exceptional customer guidance along with strong scientific and commercial excellence.
URL:https://thebiocalendar.com/event/unlocking-the-next-wave-of-cancer-vaccines-advancing-mrna-lnp-delivery-and-small-scale-manufacturing/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-21-26-Cytiva-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260421
DTEND;VALUE=DATE:20260422
DTSTAMP:20260608T065013
CREATED:20251211T120046Z
LAST-MODIFIED:20251211T120127Z
UID:9643-1776729600-1776815999@thebiocalendar.com
SUMMARY:BioLabs Investor Day Philadelphia
DESCRIPTION:More than ever\, great life science startups need extensive investor connections to be successful. That’s why BioLabs joins forces with key local ecosystem partners — drawing on our international network of investor relationships — to bring the money and the talent together. \nPhiladelphia’s third annual Investor Day event will bring together life science investors from across the country with startups from Philly’s groundbreaking ecosystem for a day of pre-selected lightning pitches\, poster sessions a lively panel of expert and invite-only networking.
URL:https://thebiocalendar.com/event/biolabs-investor-day-philadelphia/
LOCATION:Philadelphia\, Philadelphia\, PA\, United States
CATEGORIES:Investor
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260420T110000
DTEND;TZID=America/Los_Angeles:20260420T120000
DTSTAMP:20260608T065013
CREATED:20260318T142717Z
LAST-MODIFIED:20260318T142717Z
UID:10025-1776682800-1776686400@thebiocalendar.com
SUMMARY:Where Sourcing Meets Science: Performance Improvement and Cost Reduction through Innovative Collaboration
DESCRIPTION:Join this webinar to discover how variability reduction programs and animal-free peptones can optimize cell culture media for improved biotherapeutic yield\, quality\, and cost control. Learn from real-world case studies how reducing raw material variability can enhance consistency\, minimize risk\, and drive efficiency across your manufacturing process. \nKey learning objectives:\n– Demonstrating the value of peptones/yeast extracts in biotherapeutics manufacturing\n– Identifying and quantifying the cost of manufacturing variability and the benefit of process optimization in biotherapeutics\n– Demonstrating how Variability Reduction Programs successfully address raw material variability
URL:https://thebiocalendar.com/event/where-sourcing-meets-science-performance-improvement-and-cost-reduction-through-innovative-collaboration/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-20-26-Nu-Tek-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260420
DTEND;VALUE=DATE:20260422
DTSTAMP:20260608T065013
CREATED:20260316T090716Z
LAST-MODIFIED:20260316T090716Z
UID:10021-1776643200-1776815999@thebiocalendar.com
SUMMARY:ICEBB 2026: 20. International Conference on Emerging Biosensors and Biotechnology
DESCRIPTION:The International Research Conference is a federated organization dedicated to bringing together a significant number of diverse scholarly events for presentation within the conference program. Events will run over a span of time during the conference depending on the number and length of the presentations. With its high quality\, it provides an exceptional value for students\, academics and industry researchers. \nInternational Conference on Emerging Biosensors and Biotechnology aims to bring together leading academic scientists\, researchers and research scholars to exchange and share their experiences and research results on all aspects of Emerging Biosensors and Biotechnology. It also provides a premier interdisciplinary platform for researchers\, practitioners and educators to present and discuss the most recent innovations\, trends\, and concerns as well as practical challenges encountered and solutions adopted in the fields of Emerging Biosensors and Biotechnology.
URL:https://thebiocalendar.com/event/icebb-2026-20-international-conference-on-emerging-biosensors-and-biotechnology/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Summit,Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260416T110000
DTEND;TZID=America/Los_Angeles:20260416T120000
DTSTAMP:20260608T065013
CREATED:20260310T162148Z
LAST-MODIFIED:20260310T162149Z
UID:10004-1776337200-1776340800@thebiocalendar.com
SUMMARY:EU&PICS Annex 1: CCS short falls after 2 years of implementation
DESCRIPTION:This advanced webinar will focus on practical learnings to improve CCS outcomes. It has become clear that three stages of CCS preparation lead to a fully compliant live document that continues through the product life cycle.  This session addresses operational challenges and regulatory expectations across sterile manufacturing\, ATMPs\, early-phase products\, and CDMO environments.  An interactive Q&A will follow the presentation\, providing the opportunity to discuss specific operational and regulatory challenges to enhance CCS programs. An interactive Q&A will follow the presentation.
URL:https://thebiocalendar.com/event/eupics-annex-1-ccs-short-falls-after-2-years-of-implementation/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-16-26-Korber-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260416T100000
DTEND;TZID=America/Los_Angeles:20260416T120000
DTSTAMP:20260608T065013
CREATED:20260312T134959Z
LAST-MODIFIED:20260312T134959Z
UID:10013-1776333600-1776340800@thebiocalendar.com
SUMMARY:Smart Sourcing: Patient Recruitment & Retention Showcase
DESCRIPTION:A 2-hour virtual expo for clinical teams to discover and compare leading patient recruitment and engagement partners—without the time\, cost\, or travel of traditional conferences. \nChoosing the right supplier impacts enrollment timelines\, diversity goals\, and site experience. This showcase helps you evaluate multiple options in one sitting. \nWhat to expect:\n✔ Live 15-minute capability presentations from top recruitment/engagement providers\n✔ Side-by-side comparisons. See real-world capabilities.\n✔ Real-time Q&A with each presenter\n✔ Practical takeaways to accelerate enrollment\, improve diversity\, and reduce drop-off \nWhy register\nYou’ll leave with a curated shortlist of viable partners and the confidence to move faster on your next study\, saving weeks of research.
URL:https://thebiocalendar.com/event/smart-sourcing-patient-recruitment-retention-showcase-2/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-2026-CLSE-230x90-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260415T110000
DTEND;TZID=America/Los_Angeles:20260415T120000
DTSTAMP:20260608T065013
CREATED:20260319T135546Z
LAST-MODIFIED:20260319T135546Z
UID:10041-1776250800-1776254400@thebiocalendar.com
SUMMARY:OneTeam™: Setting a New Standard for Biotech Program Visibility
DESCRIPTION:Learn how to transform your gene therapy program management by adopting the OneTeam™ approach to create a transparent\, integrated “single source of truth” that replaces fragmented reporting and improves decision-making. Explore how enhanced visibility\, standardized governance\, and a shared digital interface can strengthen sponsor-CDMO collaboration and turn outsourcing from a black box into a streamlined\, confident partnership.
URL:https://thebiocalendar.com/event/oneteam-setting-a-new-standard-for-biotech-program-visibility/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-15-26-Andelyn-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260415T110000
DTEND;TZID=America/Los_Angeles:20260415T120000
DTSTAMP:20260608T065013
CREATED:20260318T143414Z
LAST-MODIFIED:20260318T143414Z
UID:10029-1776250800-1776254400@thebiocalendar.com
SUMMARY:Less Risk\, More Speed -The New Blueprint for Bioconjugate Development: A Fireside Chat
DESCRIPTION:Join this webinar to learn how an integrated CDMO+CRO model is transforming bioconjugate development by reducing risk and accelerating timelines from discovery to GMP supply. Discover actionable strategies and real-world insights to streamline your ADC and biologics programs while avoiding costly delays and late-stage failures. \nYou’ll leave with insights on:\n– How an integrated development model reduces technical & operational risk across next-gen modalities\n– Early development strategies that front-load risk identification & mitigation before it becomes costly\n– Partner and technology selection criteria — what to look for and what to avoid\n– Navigating the evolving regulatory landscape for novel bioconjugate modalities\n– Fast-track execution strategies that compress the discovery-to-GMP timeline without compromising quality
URL:https://thebiocalendar.com/event/less-risk-more-speed-the-new-blueprint-for-bioconjugate-development-a-fireside-chat/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-15-26-Abzena-Eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260415T080000
DTEND;TZID=America/Los_Angeles:20260415T170000
DTSTAMP:20260608T065013
CREATED:20260415T192650Z
LAST-MODIFIED:20260415T192650Z
UID:10210-1776240000-1776272400@thebiocalendar.com
SUMMARY:Rethinking C&Q: How Iteration & Operational Readiness Accelerate Product-to-Patient
DESCRIPTION:In this session\, we reposition C&Q as an agile lifecycle activity—one driven by incremental specification\, rolling verification\, and early alignment across Engineering\, QA\, CQV\, and Operations.
URL:https://thebiocalendar.com/event/rethinking-cq-how-iteration-operational-readiness-accelerate-product-to-patient/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-20-26-CAI-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260414T110000
DTEND;TZID=America/Los_Angeles:20260414T120000
DTSTAMP:20260608T065013
CREATED:20260313T114432Z
LAST-MODIFIED:20260313T114432Z
UID:10017-1776164400-1776168000@thebiocalendar.com
SUMMARY:Turbocharge CAR-T Manufacturing: Industrializing Cell Therapy with Perfusion
DESCRIPTION:As the field transitions toward scalable\, cost-efficient allogeneic CAR-T therapies\, manufacturing intensification is no longer optional\, it is essential. \nThis webinar demonstrates how perfusion using XCell® ATF technology enables rapid\, high-density CAR-T expansion in stirred-tank bioreactors while preserving critical quality attributes. Data from intensified 2 L perfusion processes show consistent production of >110 anti-CD19 CAR-T doses within a 12-day manufacturing cycle\, using serum-free media and optimized perfusion strategies. \nWe will present predictive scale-down modeling from Ambr® 250 STR to 2 L scale\, stable process control with matched volumetric power input (P/V)\, and real-time viable cell monitoring using multi-frequency capacitance. We will also cover seamless downstream integration with automated harvest systems such as Ksep®\, achieving >90% recovery. Attendees will gain practical insight into how perfusion using XCell® ATF System reduces timelines\, increases yields\, improves process control\, and establishes a scalable\, economically viable CAR-T manufacturing platform. \nKey Learning Objectives:\n~    How matched volumetric power input (P/V) enables predictive scale-down modeling and de-risked tech transfer from Ambr® 250 to 2 L scale\n~    Why XCell ATF perfusion delivers ~34% greater fold expansion than G-Rex® systems and how multi-frequency capacitance enables real-time viable cell density prediction\n~   How to integrate automated harvest systems (e.g.\, Ksep®) for >90% recovery in an industrialized allogeneic CAR-T workflow
URL:https://thebiocalendar.com/event/turbocharge-car-t-manufacturing-industrializing-cell-therapy-with-perfusion/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-14-26-Repligen-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260414T110000
DTEND;TZID=America/Los_Angeles:20260414T120000
DTSTAMP:20260608T065013
CREATED:20260310T161658Z
LAST-MODIFIED:20260310T161659Z
UID:10000-1776164400-1776168000@thebiocalendar.com
SUMMARY:Proactive Contamination Control in Aseptic Fill/Finish
DESCRIPTION:Join experts Herman Bozenhardt\, President of Bozenhardt Consulting\, and James Janachowski\, MS&T Site Lead\, Process Engineering for CSL Behring\, as they explore topics such as risk-based facility and equipment design\, advanced barrier technologies\, personnel and material flow optimization\, environmental monitoring trending and data analytics\, and the integration of rapid microbiological methods.
URL:https://thebiocalendar.com/event/proactive-contamination-control-in-aseptic-fill-finish/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/26_04-POL-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260414
DTEND;VALUE=DATE:20260416
DTSTAMP:20260608T065013
CREATED:20251125T143235Z
LAST-MODIFIED:20251125T143235Z
UID:9584-1776124800-1776297599@thebiocalendar.com
SUMMARY:American Biomanufacturing Summit
DESCRIPTION:The Generis American Biomanufacturing Summit (BIO) has a strong reputation as the leading platform for connecting senior leaders and exchanging ideas in the biopharma and biotech industries. This two-day conference is designed to bring together biopharma executives and solution providers to discuss emerging trends\, strategic insights\, and best practices in an ever-evolving biomanufacturing landscape. Join over 350 biopharma and biotech executive leaders\, including more than 50 speakers\, 150 senior-level attendees\, and hundreds of participants from solution companies at this annual event as we explore the latest challenges\, opportunities\, and innovations shaping the industry. With sessions led by top biotech executives\, the agenda will dive into critical topics such as AAV manufacturing\, cell and gene therapy\, capacity management\, quality assurance and control\, regulatory compliance\, operational excellence\, and supply chain and logistics. Network with fellow biopharma leaders and connect with leading solution providers as we uncover strategies to maximize efficiency and ensure compliance within the biomanufacturing space.
URL:https://thebiocalendar.com/event/american-biomanufacturing-summit/
LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260413
DTEND;VALUE=DATE:20260417
DTSTAMP:20260608T065013
CREATED:20260109T153145Z
LAST-MODIFIED:20260109T153146Z
UID:9756-1776038400-1776383999@thebiocalendar.com
SUMMARY:Drug Discovery Chemistry
DESCRIPTION:Drug Discovery Chemistry is a dynamic conference for medicinal\, biophysical\, and computational chemists working across pharma\, biotech\, and academia. Focused on discovery and optimization challenges of small-molecule and macrocyclic drug candidates\, the 2026 event features new sessions spanning AI- and ML-driven design\, fragment- and structure-based discovery\, molecular glues and degraders\, DNA-encoded libraries\, and emerging biophysical tools. Attendees can tailor their experience by exploring concurrent tracks covering today’s most innovative approaches to drug discovery.
URL:https://thebiocalendar.com/event/drug-discovery-chemistry-2/
LOCATION:San Diego\, San Diego\, CA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260413
DTEND;VALUE=DATE:20260415
DTSTAMP:20260608T065013
CREATED:20251212T172218Z
LAST-MODIFIED:20251212T172933Z
UID:9644-1776038400-1776211199@thebiocalendar.com
SUMMARY:CMO Summit 360°
DESCRIPTION:The Largest ​​​​​​​Annual Gathering of Biotech CMOs\n  \n\n\n\n\nThe 14th annual CMO Summit 360° ® is the largest gathering of biotech Chief Medical Officers across indications\, modalities\, company stages\, professional experience levels and geographic locations. This is the conference to connect with peers and develop the skills needed to succeed as a biotech CMO. \nWe are thrilled to announce that the CMO Summit 360° is now part of Fierce Life Sciences. Combining our resources allows for greater market reach\, more networking and partnering.
URL:https://thebiocalendar.com/event/cmo-summit-360-3/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260409T110000
DTEND;TZID=America/Los_Angeles:20260409T120000
DTSTAMP:20260608T065013
CREATED:20260308T190217Z
LAST-MODIFIED:20260308T190217Z
UID:9992-1775732400-1775736000@thebiocalendar.com
SUMMARY:Defined Media\, Defined Results: Scaling E. coli from Bench to Fermenter
DESCRIPTION:Microbial systems are foundational to plasmid DNA and recombinant protein production\, yet scaling from development to production often introduces variability\, performance limitations\, and regulatory complexity—especially when complex media components are involved. As organizations push for higher yields\, improved reproducibility\, and animal origin free workflows\, chemically defined solutions are becoming essential. \nIn this webinar\, Stanislav Pepeliaev Ph.D. will share firsthand insights from beta-testing at the Jenner Institute\, with the Gibco™ Bacto CD Supreme Fermentation Production Medium (FPM)  Plus and Bacto CD Supreme Feed (2x)\, a next-generation chemically defined formulation designed to enhance E. coli culture performance. He will discuss observed performance improvements\, robustness\, workflow integration\, and how defined systems can support consistent plasmid DNA and recombinant protein production. \nBuilding on this foundation\, fermentation expert Neelanjan (Neel) Sengupta Ph.D. will present a scale-up perspective—exploring how chemically defined media supports transition from bench-scale experiments to controlled single-use fermenter environments. The session concludes with a live Q&A featuring Stan\, Neel\, and Mark Wight to address implementation strategies and audience questions. \nBy attending\, participants will: \nUnderstand the performance advantages of chemically defined media in E. coli systems\nEvaluate real-world beta-test data supporting plasmid DNA workflows\nLearn practical scale-up considerations for transitioning to controlled fermenter systems
URL:https://thebiocalendar.com/event/defined-media-defined-results-scaling-e-coli-from-bench-to-fermenter/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/1772832182634.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260409
DTEND;VALUE=DATE:20260410
DTSTAMP:20260608T065013
CREATED:20260214T231312Z
LAST-MODIFIED:20260214T231312Z
UID:9906-1775692800-1775779199@thebiocalendar.com
SUMMARY:Life Sciences Future SW
DESCRIPTION:The Life Sciences Future SW conference will unite stakeholders from the region and beyond\, including life sciences start-ups\, established industry leaders\, academic institutions\, healthcare providers\, and investors. \nThis event will strengthen connections with the Southwest region while fostering new relationships across the state. The conference aims to create a more cohesive and thriving regional ecosystem that supports business growth\, innovation\, and collaboration in the life sciences sector.
URL:https://thebiocalendar.com/event/life-sciences-future-sw-2/
LOCATION:Pittsburgh\, Pittsburgh\, PA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260407T163000
DTEND;TZID=America/New_York:20260407T200000
DTSTAMP:20260608T065013
CREATED:20260325T192643Z
LAST-MODIFIED:20260327T171116Z
UID:10069-1775579400-1775592000@thebiocalendar.com
SUMMARY:Builds Bio+ NY Metro Life Science Outlook & Networking Reception
DESCRIPTION:The life sciences and biotech community navigated a historically challenging landscape in 2025. Between shifts in federal agency structures and financial hurdles on Wall Street\, the industry faced significant uncertainty. \nHowever\, innovation has not slowed down. From CRISPR gene-editing breakthroughs to AI-bolstered drug discovery and advances in materials science\, the potential for progress remains stronger than ever. \nJoin Builds Bio+ at Arnold & Porter as we analyze the initiatives driving the region forward. We will discuss the findings of Governor Hochul’s Emerging Technology Advisory Board and explore how 2026 is positioned to propel the NY Metro area to the forefront of global biotechnology. \nLocation: Arnold & Porter\,\n250 West 55th Street\,\nNew York\, NY 10019-9710
URL:https://thebiocalendar.com/event/ny-metro-life-science-outlook-networking-reception/
LOCATION:Arnold & Porter\, 250 West 55th Street\, New York\, 10019\, United States
CATEGORIES:Networking
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/480-x-270-px-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260407T100000
DTEND;TZID=America/Los_Angeles:20260409T120000
DTSTAMP:20260608T065013
CREATED:20260224T154635Z
LAST-MODIFIED:20260224T154635Z
UID:9968-1775556000-1775736000@thebiocalendar.com
SUMMARY:Cell & Gene Tech Expo
DESCRIPTION:The Cell & Gene Tech Expo is designed to aid professionals in discovering the latest advancements and equipment critical to cell and gene therapy development. Attendees will explore state-of-the-art solutions such as bioreactor systems\, cell sorting and isolation technologies\, automated platforms\, non-viral gene editing tools like electroporation and CRISPR\, data monitoring tools\, sterilization solutions\, and more. \nThis digital event is free for Cell & Gene subscribers and offers an alternative to in-person events which can be costly\, ineffective\, and time-consuming. Through this virtual platform\, professionals can effortlessly connect with various suppliers\, making the selection process more accessible and informed. \nCell Therapy Solutions – April 7\, 2026\nGene Therapy Solutions – April 8\, 2026\nCommercial Readiness – April 9\, 2026
URL:https://thebiocalendar.com/event/cell-gene-tech-expo/
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/02/cellgeneexpo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260331T110000
DTEND;TZID=America/Los_Angeles:20260331T120000
DTSTAMP:20260608T065013
CREATED:20260303T140956Z
LAST-MODIFIED:20260303T140956Z
UID:9983-1774954800-1774958400@thebiocalendar.com
SUMMARY:The Phase 2 Endpoint Dilemma: Bridging Subjective Scales and Objective Measures in Neurodegenerative Trials
DESCRIPTION:Phase 2 neurodegenerative trials are increasingly challenged by slow disease trajectories\, heterogeneous patient populations\, and blunt legacy endpoints that struggle to detect treatment-related change over typical study durations. Traditional scales such as ADAS-Cog and MDS-UPDRS\, while well-established\, often lack sensitivity in early disease\, are vulnerable to rater and practice effects\, and may insufficiently capture subtle but clinically meaningful benefits. \nThis webinar will examine when and how to move beyond single-scale approaches toward more informative composite strategies\, highlighting circumstances in which composites enhance signal detection versus when they introduce additional noise\, complexity\, and interpretability risk. We will explore practical frameworks for integrating functional\, cognitive\, and biomarker measures into coherent endpoint hierarchies that support both mechanistic insight and regulatory relevance. Finally\, we will discuss how real-world evidence and natural history data can be leveraged to select\, calibrate\, and power Phase 2 endpoints capable of detecting meaningful change within shorter trial timeframes\, improving go/no-go decision quality for emerging neurodegenerative therapies. \nKey Learning Objectives:\n– Evaluate the strengths and limitations of traditional subjective scales (e.g.\, ADAS-Cog\, MDS-UPDRS) in Phase 2 neurodegenerative trials and identify when alternative or composite strategies are warranted \n– Apply practical frameworks to integrate cognitive\, functional\, and biomarker endpoints into coherent\, regulator-ready hierarchies that enhance signal detection while minimizing interpretability risk \n– Leverage real-world evidence and natural history datasets to inform endpoint selection\, calibration\, and powering strategies that improve Phase 2 go/no-go decision-making
URL:https://thebiocalendar.com/event/the-phase-2-endpoint-dilemma-bridging-subjective-scales-and-objective-measures-in-neurodegenerative-trials/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/Untitled-design-59.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260331T110000
DTEND;TZID=America/Los_Angeles:20260331T120000
DTSTAMP:20260608T065013
CREATED:20260220T125345Z
LAST-MODIFIED:20260220T125345Z
UID:9947-1774954800-1774958400@thebiocalendar.com
SUMMARY:Digital Design Meets Proven Performance: The Future of Single-Use Assemblies
DESCRIPTION:In today’s fast-paced biopharma and CDMO environments\, single-use assembly design is about confidence in quality\, supply continuity\, and process performance. This webinar explores how Thermo Scientific™ Single-Use Assemblies are designed to help reduce risk\, support flexible manufacturing\, and help organizations meet production milestones and maintain momentum when time to market is crucial. \nAttendees will see how automation-driven tools – including the Kaon™ app and the online Single-Use Assembly Configurator\, simplify and standardize assembly design. By bringing a broad\, trusted portfolio of components into one intuitive digital experience\, these tools accelerate design decisions\, improve consistency\, and reduce the effort required to move from concept to execution. \nWe will highlight three core considerations that set Thermo Scientific Single-Use Assemblies apart and deliver tangible value in real-world bioprocessing operations: \n    ~ Film technology for durable\, consistent performance across 2D and 3D bioprocess containers\n    ~ Integration of LifeASSURE™ sterilizing grade filters that streamline qualification\n    ~ Protection of process integrity at critical connection points to reduce risks of leaks \nJoin this webinar to learn how a standardized\, automated configuration experience\, backed by proven Thermo Scientific technologies to help biopharma and CDMO teams move faster\, reduce risk\, and execute with confidence.
URL:https://thebiocalendar.com/event/digital-design-meets-proven-performance-the-future-of-single-use-assemblies/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/02/03-31-26-Thermo-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260326T130000
DTEND;TZID=America/Los_Angeles:20260326T140000
DTSTAMP:20260608T065013
CREATED:20260224T125549Z
LAST-MODIFIED:20260224T125716Z
UID:9961-1774530000-1774533600@thebiocalendar.com
SUMMARY:Why Open-Source Models Matter for Computational Drug Discovery
DESCRIPTION:AI is reshaping every industry—and drug discovery is no exception. Across targets\, molecules\, and data at massive scale\, AI is becoming integral to how modern therapeutics are discovered and developed. \nThis panel explores how foundational open‑source AI engines like OpenFold and Boltz are being used across the drug discovery workflow\, from target discovery and validation to hit identification and lead optimization. Panelists will discuss the growing role of structural modeling\, chemoinformatics\, and predictive machine learning\, including how open models can enable faster structure–activity insights\, earlier toxicity prediction\, and more efficient decision‑making. The conversation will also touch on antibiotic discovery\, where AI is helping researchers break through long‑standing scientific and economic barriers by identifying new mechanisms\, molecular scaffolds\, and design strategies. \nThis session is designed for scientists and leaders seeking to understand where open-source AI is delivering real impact today—and why AI is no longer optional for staying competitive in drug discovery.
URL:https://thebiocalendar.com/event/why-open-source-models-matter-for-computational-drug-discovery/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/02/26_03-DDO-NL-468x60-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260326T130000
DTEND;TZID=America/Los_Angeles:20260326T140000
DTSTAMP:20260608T065013
CREATED:20260220T124433Z
LAST-MODIFIED:20260220T124433Z
UID:9943-1774530000-1774533600@thebiocalendar.com
SUMMARY:Avoiding Scale-Up Surprises: Applying AI and Rapid Prototyping to Media and Process Development
DESCRIPTION:As biologics grow more complex and development timelines continue to tighten\, many teams could encounter manufacturability challenges related to decisions around media\, process\, and scalability made earlier in development. Traditional\, sequential workflows may not always surface potential challenges until programs are already moving toward scale-up\, which can limit flexibility. \nIn this webinar\, Thermo Fisher Scientific experts discuss factors that contribute to manufacturability challenges during the transition from development to manufacturing. The session walks through a representative development journey\, including early insights from AI\, data modeling\, and analytical testing\, followed by media and process development\, qualification through rapid prototyping\, and considerations for large-scale cGMP manufacturing. \nDuring this session\, attendees will hear perspectives on how teams may:\n~ Consider manufacturability earlier in biologics development\n~ Inform development decisions with AI and data modeling\n~ Apply rapid prototyping to evaluate media and process choices\n~ Support development decisions prior to cGMP scale-up
URL:https://thebiocalendar.com/event/avoiding-scale-up-surprises-applying-ai-and-rapid-prototyping-to-media-and-process-development/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/02/03-26-26-Thermo-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260326T080000
DTEND;TZID=America/Los_Angeles:20260326T170000
DTSTAMP:20260608T065013
CREATED:20260212T142522Z
LAST-MODIFIED:20260218T164505Z
UID:9896-1774512000-1774544400@thebiocalendar.com
SUMMARY:Charles River Cell & Gene Therapy Summit
DESCRIPTION:Returning to Boston this March \n\n\n\n\n\n\n\n\n\n\n\n\nConnect with Fellow Leaders Shaping Cell and Gene Therapy Development\n\n\n\n\n\n\n\n\n\n\n\n\n  \nThe eighth in a series of premier one-day events held in the world’s biggest biotech hubs\, Charles River is bringing together the leading experts\, executives\, and thought leaders in the CGT space to discuss and navigate critical challenges. \nRegister today to save your seat for an exclusive event aimed to inspire\, educate\, and connect you with the people shaping the future of advanced therapies.
URL:https://thebiocalendar.com/event/charles-river-cell-gene-therapy-summit/
LOCATION:Cambridge\, MA\, Cambridge\, MA\, 02139\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260326T060000
DTEND;TZID=America/Los_Angeles:20260326T070000
DTSTAMP:20260608T065013
CREATED:20260310T161448Z
LAST-MODIFIED:20260310T161448Z
UID:9996-1774504800-1774508400@thebiocalendar.com
SUMMARY:2026 Manufacturing Trends Reshaping Life Sciences: AI\, Integration\, and Workforce Readiness
DESCRIPTION:Learn how leading manufacturers are connecting manufacturing\, quality\, and supply chain systems to improve visibility\, accelerate decision making and create more agile operations. The session will explore how organizations are strengthening supply chains and preparing their workforce for increasingly digital manufacturing environments.
URL:https://thebiocalendar.com/event/2026-manufacturing-trends-reshaping-life-sciences-ai-integration-and-workforce-readiness/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/03-26-26-MasterControl-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260325
DTEND;VALUE=DATE:20260328
DTSTAMP:20260608T065013
CREATED:20260212T143153Z
LAST-MODIFIED:20260212T143234Z
UID:9898-1774396800-1774655999@thebiocalendar.com
SUMMARY:LSX World Congress Europe
DESCRIPTION:LSX World Europe (LSX Europe) is a leading life science fundraising and investment event\, bringing innovators and investors together through strategic 1:1 meetings and targeted networking. \nEarly-stage (Seed–Series B) biotech\, medical device\, diagnostics and digital health companies\, including university spin-outs – join to secure investment and build collaborations. \nActive life science investors attend\, looking for new investments and syndication. \nThrough our proven partnering format\, conversations turn into real partnerships and successful raises.
URL:https://thebiocalendar.com/event/lsx-world-congress-europe/
LOCATION:Lisbon\, Lisbon\, Portugal
CATEGORIES:Partnering
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260324T130000
DTEND;TZID=America/Los_Angeles:20260324T140000
DTSTAMP:20260608T065013
CREATED:20260218T144306Z
LAST-MODIFIED:20260218T144306Z
UID:9912-1774357200-1774360800@thebiocalendar.com
SUMMARY:From Breakdown to Breakthrough: The Maturity Journey for Asset Performance Management (APM)
DESCRIPTION:Asset Performance Management (APM) has evolved far beyond reactive maintenance – but many organizations are still navigating how to get there.  In this session\, Chief Platform Architect at Blue Mountain\, Bill Lucas\, walks through the industry’s APM maturity journey\, tracing the shift from breakdown-driven maintenance to predictive and AI-powered optimization.
URL:https://thebiocalendar.com/event/from-breakdown-to-breakthrough-the-maturity-journey-for-asset-performance-management-apm/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/02/03-24-26-Blue-Mountain-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260324T110000
DTEND;TZID=America/Los_Angeles:20260324T120000
DTSTAMP:20260608T065013
CREATED:20260225T150248Z
LAST-MODIFIED:20260225T150248Z
UID:9976-1774350000-1774353600@thebiocalendar.com
SUMMARY:Flexible Therapeutic Development: Balancing Speed\, Cost\, and Process
DESCRIPTION:Explore how KBI Biopharma delivers fast\, cost-effective\, and robust microbial protein process development\, tailored for first-in-human (FIH\, Phase I) programs and adaptable to each client’s needs for speed\, cost\, and performance. \nLearning Objectives:\n– Key considerations for microbial cell line\, fermentation\, and purification development for FIH\n– How milestones align from proof-of-concept to toxicology material\n– How platform-based and robotic workflows can optimize cost\, speed\, or robustness—no license fee required
URL:https://thebiocalendar.com/event/flexible-therapeutic-development-balancing-speed-cost-and-process/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/02/03-24-26-KBI-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260324T110000
DTEND;TZID=America/Los_Angeles:20260324T120000
DTSTAMP:20260608T065013
CREATED:20260223T130511Z
LAST-MODIFIED:20260223T130511Z
UID:9951-1774350000-1774353600@thebiocalendar.com
SUMMARY:Process Control's Increasing Role in Biosimilar Approval
DESCRIPTION:Regulators are moving the comparability goalpost\, shifting the burden of proof from massive clinical trials to deep process understanding. In this new landscape\, the ability to define and control CPPs is the only way to ensure a biosimilar remains highly similar to its reference. \nJoin Bioprocess Online’s Jon O’Connell for a virtual Q&A with experts exploring how QbD principles and an understanding of reference product CQAs should guide biosimilar process development to smooth the path to regulatory approval.  \nThis Bioprocess Online Live event will feature industry veterans\, biosimilars experts and principal consultants who will offer guidance and insight you won’t want to miss.
URL:https://thebiocalendar.com/event/process-controls-increasing-role-in-biosimilar-approval/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/02/1771601868346.png
END:VEVENT
END:VCALENDAR